Gemcabene

• Description :

  Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity[1][2][3].

• Product Name Alternative :

  PD-72953

• UNSPSC :

  12352211

• Target :

  Others

• Type :

  Reference compound

• Related Pathways :

  Others

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Metabolic Disease; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/gemcabene.html

• Purity :

  99.91

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O

• Molecular Formula :

  C16H30O5

• Molecular Weight :

  302.41

• References & Citations :

  [1]Mandema JW, et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 2005 Oct 7;7 (3) :E513-22.|[2]Srivastava RAK, et al. Gemcabene, a First-in-Class Hypolipidemic Small Molecule in Clinical Development, Attenuates Osteoarthritis and Pain in Animal Models of Arthritis and Pain. Front Pharmacol. 2018 May 11;9:471.|[3]Oniciu DC, et al. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH. PLoS One. 2018 May 30;13 (5) :e0194568.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [183293-82-5]